Back to results
US 6,011,003 AGranted
FLT-4(FMS-like tyrosine kinase), FLT-15, variants thereof used as growth factor inhibitors
AssigneeMetris Therapeutics Limited
InventorsDavid Stephen Charnock-Jones, Christine Ann Boocock, Andrew Mark Sharkey, Stephen Kevin Smith
Life of this patent
Estimating the term…
Abstract
Disclosed is an altered, soluble form of the FLT polypeptide being capable of binding to VEGF and thereby exerting an inhibitory effect thereon, the polypeptide comprising five or fewer complete immunoglobulin-like domains, together with pharmaceutical compositions comprising the polypeptide, and various uses thereof.
Claims6
An isolated, soluble polypeptide selected from the group consisting of:
- (a) a polypeptide having an amino acid sequence consisting of amino acid residues 1 to 553 of SEQ ID NO:3;
- (b) a polypeptide having an amino acid sequence consisting of amino acid residues 1 to 517 of SEQ ID NO:3;
- (c) a polypeptide having an amino acid sequence consisting of amino acid residues 1 to 553 of SEQ ID NO:3 with the addition of the sequence ELSNFECLHPCSQE (SEQ ID NO:16) at its C-terminal end;
- (d) a polypeptide having an amino acid sequence consisting of amino acid residues 1 to 517 of SEQ ID NO:3 with the addition of the sequence LPPADSSFMLPPTSFSSNYFHFLP (SEQ ID NO:17) at its C-terminal end;
- and
- (e) a truncated variant polypeptide of (a), (b), (c) or (d);
- wherein said truncated variant polypeptide consists of no more than five complete immunoglobulin-like domains;
- and wherin said trucated variant polypeptide both binds to and exerts an inhibitory effect on VEGF.
5 more elements
Dependencies are inferred from the claim text.